Management and therapeutic perspectives in amyotrophic lateral sclerosis

References

• Harper CJ, Sorenson EJ, Mandrekar J. Epidemiology of amyotrophic lateral sclerosis in Minnesota: A year-long population based study. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:520–523.
   PubMed Web of Science ®Google Scholar
• Rowland LP. How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch Neurol. 2001;58:512–515.
   PubMed Web of Science ®Google Scholar
• Charcot JM. De la sclérose latérale amyotrophique. Progr Med. 1874;2:325–327; 341–342; 453–455.
   Google Scholar
• Turner MR, Swash M. The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey. J Neurol Neurosurg Psychiatry. 2015;86:667–673.
   PubMed Web of Science ®Google Scholar
• Talbot K. Motor neurone disease. Postgrad Med J. 2002;78:513–519.
   PubMed Web of Science ®Google Scholar
• Caress JB, Ciarlone SL, Sullivan EA, et al. Natural history of muscle cramps in amyotrophic lateral sclerosis. Muscle Nerve. 2015;53:513–517.
   PubMed Web of Science ®Google Scholar
• Van Den Berg LH. Therapy of amyotrophic lateral sclerosis remains a challenge. Lancet Neurol. 2014;13:1062–1063.
   PubMed Web of Science ®Google Scholar
• Marin B, Couratier P, Arcuti S, et al. Stratification of ALS patients’ survival: a population-based study. J Neurol. 2015;263:100–111.
   PubMed Web of Science ®Google Scholar
• Hubers A, Ludolph AC, Rosenbohm A, et al. Amyotrophe Lateralsklerose: Eine Multisystemdegeneration. Nervenarzt. 2016;87:179–188.
   PubMed Web of Science ®Google Scholar
• Spalloni A, Longone P. Cognitive impairment in amyotrophic lateral sclerosis, clues from the SOD1 mouse. Neurosci Biobehav Rev. 2016;60:12–25.
   PubMed Web of Science ®Google Scholar
• Anderson TJ, MacAskill MR. Eye movements in patients with neurodegenerative disorders. Nat Rev Neurol. 2013;9:74–85.
   PubMed Web of Science ®Google Scholar
• Donaghy C, Thurtell MJ, Pioro EP, et al. Eye movements in amyotrophic lateral sclerosis and its mimics: a review with illustrative cases. J Neurol Neurosurg Psychiatry. 2011;82:110–116.
   PubMed Web of Science ®Google Scholar
• Pradat P-F, Bruneteau G, Munerati E, et al. Extrapyramidal stiffness in patients with amyotrophic lateral sclerosis. Mov Disord. 2009;24:2143–2148.
   PubMed Web of Science ®Google Scholar
• Iglesias C, Sangari S, El Mendili MM, et al. Electrophysiological and spinal imaging evidences for sensory dysfunction in amyotrophic lateral sclerosis. BMJ Open. 2015;5:e007659.
   PubMed Web of Science ®Google Scholar
• Truini A, Biasiotta A, Onesti E, et al. Small-fibre neuropathy related to bulbar and spinal-onset in patients with ALS. J Neurol. 2015;262:1014–1018.
   PubMed Web of Science ®Google Scholar
• Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009;73:805–811.
   PubMed Web of Science ®Google Scholar
• Hsieh S, Caga J, Leslie FV, et al. Cognitive and behavioral symptoms in ALSFTD: detection, differentiation, and progression. J Geriatr Psychiatry Neurol. 2016;29:3–10.
   PubMed Web of Science ®Google Scholar
• Singer MA, Statland JM, Wolfe GI, et al. Primary lateral sclerosis. Muscle Nerve. 2007;35:291–302.
   PubMed Web of Science ®Google Scholar
• Wijesekera LC, Mathers S, Talman P, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology. 2009;72:1087–1094.
   PubMed Web of Science ®Google Scholar
• Rowland LP. Progressive muscular atrophy and other lower motor neuron syndromes of adults. Muscle Nerve. 2010;41:161–165.
   PubMed Web of Science ®Google Scholar
• Ludolph A, Drory V, Hardiman O, et al. A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:291–292.
   PubMed Web of Science ®Google Scholar
• Couratier P, Torny F, Lacoste M. Echelles fonctionnelles de la sclérose latérale amyotrophique. Rev Neurol (Paris). 2006;162:502–507.
   PubMed Web of Science ®Google Scholar
• Benatar M, Boylan K, Jeromin A, et al. ALS biomarkers for therapy development: state of the field & future directions. Muscle Nerve. 2016;53:169–182.
   Web of Science ®Google Scholar
• Hayashi Y, Homma K, Ichijo H. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS. Adv Biol Regul. 2015;60:95–104.
   PubMedGoogle Scholar
• Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257–268.
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–256.
   PubMed Web of Science ®Google Scholar
• McGoldrick P, Joyce PI, Fisher EM, et al. Rodent models of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2013;1832:1421–1436.
   PubMed Web of Science ®Google Scholar
• Lee S, Huang EJ. Modeling ALS and FTD with iPSC-derived neurons. Brain Res. 2015;pii: S0006-8993(15)00740-4.
   Google Scholar
• Le Masson G, Przedborski S, Abbott LF. A computational model of motor neuron degeneration. Neuron. 2014;83:975–988.
   PubMed Web of Science ®Google Scholar
• Strong M, Rosenfeld J. Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:136–143.
   PubMed Web of Science ®Google Scholar
• Ludolph AC, Meyer T, Riepe MW. The role of excitotoxicity in ALS–what is the evidence? J Neurol. 2000;247:S7–16.
   Web of Science ®Google Scholar
• Spencer PS. Guam ALS/parkinsonism-dementia: a long-latency neurotoxic disorder caused by “slow toxin(s)” in food? Can J Neurol Sci. 1987;14:347–357.
   PubMed Web of Science ®Google Scholar
• Gresham LS, Molgaard CA, Golbeck AL, et al. Amyotrophic lateral sclerosis and occupational heavy metal exposure: a case-control study. Neuroepidemiology. 1986;5:29–38.
   PubMedGoogle Scholar
• Armon C. An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology. 2003;22:217–228.
   PubMed Web of Science ®Google Scholar
• Gunnarsson LG, Lindberg G, Söderfeldt B, et al. Amyotrophic lateral sclerosis in Sweden in relation to occupation. Acta Neurol Scand. 1991;83:394–398.
   PubMed Web of Science ®Google Scholar
• Chancellor AM, Slattery JM, Fraser H, et al. Risk factors for motor neuron disease: a case-control study based on patients from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry. 1993;56:1200–1206.
   PubMed Web of Science ®Google Scholar
• Neilson S, Robinson I, Alperovitch A. Rising amyotrophic lateral sclerosis mortality in France 1968-1990: increased life expectancy and inter-disease competition as an explanation. J Neurol. 1994;241:448–455.
   PubMed Web of Science ®Google Scholar
• Valenti M, Pontieri FE, Conti F, et al. Amyotrophic lateral sclerosis and sports: a case-control study. Eur J Neurol. 2005;12:223–225.
   PubMed Web of Science ®Google Scholar
• Piazza O, Siren AL, Ehrenreich H. Soccer, neurotrauma and amyotrophic lateral sclerosis: is there a connection? Curr Med Res Opin. 2004;20:505–508.
   PubMed Web of Science ®Google Scholar
• Li C-Y, Sung F-C. Association between occupational exposure to power frequency electromagnetic fields and amyotrophic lateral sclerosis: a review. Am J Ind Med. 2003;43:212–220.
   PubMed Web of Science ®Google Scholar
• Hafezparast M, Ahmad-Annuar A, Hummerich H, et al. Paradigms for the identification of new genes in motor neuron degeneration. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:249–257.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Risk factors in amyotrophic lateral sclerosis. Adv Neurol. 1991;56:245–270.
   PubMedGoogle Scholar
• King AE, Woodhouse A, Kirkcaldie MT, et al. Excitotoxicity in ALS: overstimulation, or overreaction? Exp Neurol. 2015;275:162–171.
   PubMed Web of Science ®Google Scholar
• Tadic V, Prell T, Lautenschlaeger J, et al. The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis. Front Cell Neurosci. 2014;8:147.
   PubMed Web of Science ®Google Scholar
• Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47:S233–241.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–591.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology. 1996;47:S242–S250.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, et al. An outcome study of riluzole in amyotrophic lateral sclerosis–a population-based study in Ireland, 1996-2000. J Neurol. 2003;250:473–479.
   PubMed Web of Science ®Google Scholar
• Forbes RB, Colville S, Cran GW, et al. Unexpected decline in survival from amyotrophic lateral sclerosis/motor neurone disease. J Neurol Neurosurg Psychiatry. 2004;75:1753–1755.
   PubMed Web of Science ®Google Scholar
• Sorenson EJ, Stalker AP, Kurland LT, et al. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology. 2002;59:280–282.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;3:CD001447.
   PubMed Web of Science ®Google Scholar
• Andersen PM, Borasio GD, Dengler R, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol. 2005;12:921–938.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Delumeau JC, et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249:609–615.
   PubMed Web of Science ®Google Scholar
• Indo HP, Davidson M, Yen HC, et al. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion. 2007;7:106–118.
   PubMed Web of Science ®Google Scholar
• Finelli MJ, Sanchez-Pulido L, Liu KX, et al. The evolutionarily conserved Tre2/Bub2/Cdc16 (TBC), Lysin motif (LysM), Domain catalytic (TLDc) domain is neuroprotective against oxidative stress. J Biol Chem. 2015;291:2751–2763.
   PubMed Web of Science ®Google Scholar
• Finelli MJ, Liu KX, Wu Y, et al. Oxr1 improves pathogenic cellular features of ALS-associated FUS and TDP-43 mutations. Hum Mol Genet. 2015;24:3529–3544.
   PubMed Web of Science ®Google Scholar
• Kaus A, Sareen D. ALS patient stem cells for unveiling disease signatures of motoneuron susceptibility: perspectives on the deadly mitochondria, ER stress and calcium triad. Front Cell Neurosci. 2015;9:448.
   PubMed Web of Science ®Google Scholar
• Miquel E, Cassina A, Martínez-Palma L, et al. Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis. PLoS One. 2012;7:e34776.
   PubMed Web of Science ®Google Scholar
• Palomo GM, Manfredi G. Exploring new pathways of neurodegeneration in ALS: the role of mitochondria quality control. Brain Res. 2015;1607:36–46.
   PubMed Web of Science ®Google Scholar
• Natale G, Lenzi P, Lazzeri G, et al. Compartment-dependent mitochondrial alterations in experimental ALS, the effects of mitophagy and mitochondriogenesis. Front Cell Neurosci. 2015;9:434.
   PubMed Web of Science ®Google Scholar
• Ruffoli R, Bartalucci A, Frati A, et al. Ultrastructural studies of ALS mitochondria connect altered function and permeability with defects of mitophagy and mitochondriogenesis. Front Cell Neurosci. 2015;9:341.
   PubMed Web of Science ®Google Scholar
• Kametani F, Obi T, Shishido T, et al. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci Rep. 2016;6:23281.
   PubMed Web of Science ®Google Scholar
• Feiler MS, Strobel B, Freischmidt A, et al. TDP-43 is intercellularly transmitted across axon terminals. J Cell Biol. 2015;211:897–911.
   PubMed Web of Science ®Google Scholar
• Fujii S, Takanashi K, Kitajo K, et al. Treatment with a global methyltransferase inhibitor induces the intranuclear aggregation of ALS-linked FUS mutant in vitro. Neurochem Res. 2016;41:826–835.
   PubMed Web of Science ®Google Scholar
• Redler RL, Dokholyan NV. The complex molecular biology of amyotrophic lateral sclerosis (ALS). Prog Mol Biol Transl Sci. 2012;107:215–262.
   PubMed Web of Science ®Google Scholar
• Aulas A, Vande Velde C. Alterations in stress granule dynamics driven by TDP-43 and FUS: a link to pathological inclusions in ALS? Front Cell Neurosci. 2015;9:423.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20–38.
   PubMed Web of Science ®Google Scholar
• Schmidt R, De Reus MA, Scholtens LH, et al. Simulating disease propagation across white matter connectome reveals anatomical substrate for neuropathology staging in amyotrophic lateral sclerosis. Neuroimage. 2016;124:762–769.
   PubMed Web of Science ®Google Scholar
• McCluskey LF, Elman LB, Martinez-Lage M, et al. Amyotrophic lateral sclerosis-plus syndrome with TAR DNA-binding protein-43 pathology. Arch Neurol. 2009;66:121–124.
   PubMed Web of Science ®Google Scholar
• Kalmar B, Lu C-H, Greensmith L. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: the therapeutic potential of Arimoclomol. Pharmacol Ther. 2014;141:40–54.
   PubMed Web of Science ®Google Scholar
• Ayers JI, Fromholt SE, O’Neal VM, et al. Prion-like propagation of mutant SOD1 misfolding and motor neuron disease spread along neuroanatomical pathways. Acta Neuropathol. 2016;131:103–114.
   PubMed Web of Science ®Google Scholar
• Braak H, Brettschneider J, Ludolph AC, et al. Amyotrophic lateral sclerosis–a model of corticofugal axonal spread. Nat Rev Neurol. 2013;9:708–714.
   PubMed Web of Science ®Google Scholar
• Baker MR. ALS–dying forward, backward or outward? Nat Rev Neurol. 2014;10:660.
   PubMed Web of Science ®Google Scholar
• Langellotti S, Romano V, Romano G, et al. A novel Drosophila model of TDP-43 proteinopathies: N-terminal sequences combined with the Q/N domain induce protein functional loss and locomotion defects. Dis Model Mech. 2016;9:659–669. pii:dmm.023382
   PubMed Web of Science ®Google Scholar
• Komine O, Yamanaka K. Neuroinflammation in motor neuron disease. Nagoya J Med Sci. 2015;77:537–549.
   PubMed Web of Science ®Google Scholar
• Mizwicki MT, Fiala M, Magpantay L, et al. Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegener Dis. 2012;1:305–315.
   PubMedGoogle Scholar
• Liu G, Fiala M, Mizwicki MT, et al. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis. 2012;1:60–74.
   PubMedGoogle Scholar
• Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10:615–622.
   PubMed Web of Science ®Google Scholar
• Rodrigues MC, Hernandez-Ontiveros DG, Louis MK, et al. Neurovascular aspects of amyotrophic lateral sclerosis. Int Rev Neurobiol. 2012;102:91–106.
   PubMed Web of Science ®Google Scholar
• Evans MC, Couch Y, Sibson N, et al. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci. 2013;53:34–41.
   PubMed Web of Science ®Google Scholar
• Morcuende S, Munoz-Hernandez R, Benitez-Temino B, et al. Neuroprotective effects of NGF, BDNF, NT-3 and GDNF on axotomized extraocular motoneurons in neonatal rats. Neuroscience. 2013;250:31–48.
   PubMed Web of Science ®Google Scholar
• Harandi VM, Lindquist S, Kolan SS, et al. Analysis of neurotrophic factors in limb and extraocular muscles of mouse model of amyotrophic lateral sclerosis. PLoS One. 2014;9:e109833.
   PubMed Web of Science ®Google Scholar
• Azzouz M, Poindron P, Guettier S, et al. Prevention of mutant SOD1 motoneuron degeneration by copper chelators in vitro. J Neurobiol. 2000;42:49–55.
   PubMedGoogle Scholar
• Dennys CN, Armstrong J, Levy M, et al. Chronic inhibitory effect of riluzole on trophic factor production. Exp Neurol. 2015;271:301–307.
   PubMed Web of Science ®Google Scholar
• ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology. 1996;46:1244–1249.
   PubMed Web of Science ®Google Scholar
• Blasco H, Guennoc AM, Veyrat-Durebex C, et al. Amyotrophic lateral sclerosis: a hormonal condition? Amyotroph Lateral Scler. 2012;13:585–588.
   PubMed Web of Science ®Google Scholar
• Mendez P, Wandosell F, Garcia-Segura LM. Cross-talk between estrogen receptors and insulin-like growth factor-I receptor in the brain: cellular and molecular mechanisms. Front Neuroendocrinol. 2006;27:391–403.
   PubMed Web of Science ®Google Scholar
• Numakawa T, Yokomaku D, Richards M, et al. Functional interactions between steroid hormones and neurotrophin BDNF. World J Biol Chem. 2010;1:133–143.
   PubMedGoogle Scholar
• Manjaly ZR, Scott KM, Abhinav K, et al. The sex ratio in amyotrophic lateral sclerosis: a population based study. Amyotroph Lateral Scler. 2010;11:439–442.
   PubMed Web of Science ®Google Scholar
• McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med. 2010;7:557–570.
   PubMed Web of Science ®Google Scholar
• Georgoulopoulou E, Vinceti M, Bonvicini F, et al. Changing incidence and subtypes of ALS in Modena, Italy: a 10-years prospective study. Amyotroph Lateral Scler. 2011;12:451–457.
   PubMed Web of Science ®Google Scholar
• Choi C-I, Lee Y-D, Gwag BJ, et al. Effects of estrogen on lifespan and motor functions in female hSOD1 G93A transgenic mice. J Neurol Sci. 2008;268:40–47.
   PubMed Web of Science ®Google Scholar
• Nefussy B, Hirsch J, Cudkowicz ME, et al. Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis. J Neurol Sci. 2011;300:23–27.
   PubMed Web of Science ®Google Scholar
• Drory VE, Bronipolsky T, Artamonov I, et al. Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2008;273:81–83.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Pradat P-F, Ludolph AC, et al. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75–82.
   PubMed Web of Science ®Google Scholar
• Zhang K, Shi P, An T, et al. Food restriction-induced autophagy modulates degradation of mutant SOD1 in an amyotrophic lateral sclerosis mouse model. Brain Res. 2013;1519:112–119.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Lange DJ, Voustianiouk A, et al. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci. 2006;7:29.
   PubMed Web of Science ®Google Scholar
• Zhao W, Varghese M, Vempati P, et al. Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease. PLoS One. 2012;7:e49191.
   PubMed Web of Science ®Google Scholar
• Ari C, Poff AM, Held HE, et al. Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model. PLoS One. 2014;9:e103526.
   PubMed Web of Science ®Google Scholar
• Dorst J, Cypionka J, Ludolph AC. High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:533–536.
   PubMed Web of Science ®Google Scholar
• Dorst J, Dupuis L, Petri S, et al. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study. J Neurol. 2015;262:849–858.
   PubMed Web of Science ®Google Scholar
• Wills A-M, Hubbard J, Macklin EA, et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;383:2065–2072.
   PubMed Web of Science ®Google Scholar
• Khan S, Ahmad K, Alshammari EM, et al. Implication of Caspase-3 as a common therapeutic target for multineurodegenerative disorders and its inhibition using nonpeptidyl natural compounds. Biomed Res Int. 2015;2015:1–9.
   Web of Science ®Google Scholar
• Martin LJ, Price AC, Kaiser A, et al. Mechanisms for neuronal degeneration in amyotrophic lateral sclerosis and in models of motor neuron death (Review). Int J Mol Med. 2000;5:3–13.
   PubMed Web of Science ®Google Scholar
• Li M, Ona VO, Guégan C, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science. 2000;288:335–339.
   PubMed Web of Science ®Google Scholar
• Boston-Howes W, Gibb SL, Williams EO, et al. Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J Biol Chem. 2006;281:14076–14084.
   PubMed Web of Science ®Google Scholar
• Morfini GA, Bosco DA, Brown H, et al. Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase. PLoS One. 2013;8:e65235.
   PubMed Web of Science ®Google Scholar
• Magrané J, Cortez C, Gan W-B, et al. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum Mol Genet. 2014;23:1413–1424.
   PubMed Web of Science ®Google Scholar
• Alami NH, Smith RB, Carrasco MA, et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014;81:536–543.
   PubMed Web of Science ®Google Scholar
• Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723–749.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87:12–20.
   PubMed Web of Science ®Google Scholar
• Hu J-H, Zhang H, Wagey R, et al. Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J Neurochem. 2003;85:432–442.
   PubMed Web of Science ®Google Scholar
• Scarrott JM, Herranz-Martín S, Alrafiah AR, et al. Current developments in gene therapy for amyotrophic lateral sclerosis. Expert Opin Biol Ther. 2015;15:935–947.
   PubMed Web of Science ®Google Scholar
• Ralph GS, Radcliffe PA, Dm D, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med. 2005;11:429–433.
   PubMed Web of Science ®Google Scholar
• Raoul C, Abbas-Terki T, Bensadoun J-C, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med. 2005;11:423–428.
   PubMed Web of Science ®Google Scholar
• Foust KD, Salazar DL, Likhite S, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther. 2013;21:2148–2159.
   PubMed Web of Science ®Google Scholar
• Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 2006;116:2290–2296.
   PubMed Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435–442.
   PubMed Web of Science ®Google Scholar
• Donnelly CJ, Zhang PW, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415–428.
   PubMed Web of Science ®Google Scholar
• Gotkine M, Rozenstein L, Einstein O, et al. Presymptomatic treatment with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS (G93A-SOD1) mice. Biomed Res Int. 2013;2013:845345.
   PubMedGoogle Scholar
• Koval ED, Shaner C, Zhang P, et al. Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum Mol Genet. 2013;22:4127–4135.
   PubMed Web of Science ®Google Scholar
• Mazzini L, Vescovi A, Cantello R, et al. Stem cells therapy for ALS. Expert Opin Biol Ther. 2016;16:187–199.
   PubMed Web of Science ®Google Scholar
• Mao Z, Zhang S, Chen H. Stem cell therapy for amyotrophic lateral sclerosis. Cell Regen. 2015;4:11.
   PubMedGoogle Scholar
• Eve DJ, Ehrhart J, Zesiewicz T, et al. Plasma derived from human umbilical cord blood modulates mitogen-induced proliferation of mononuclear cells isolated from the peripheral blood of ALS patients. Cell Transplant. 2016;25:963–971.
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Willing AE, Milliken M, et al. Positive effect of transplantation of hNT neurons (NTera 2/D1 cell-line) in a model of familial amyotrophic lateral sclerosis. Exp Neurol. 2002;174:169–180.
   PubMed Web of Science ®Google Scholar
• Hemendinger R, Wang J, Malik S, et al. Sertoli cells improve survival of motor neurons in SOD1 transgenic mice, a model of amyotrophic lateral sclerosis. Exp Neurol. 2005;196:235–243.
   PubMed Web of Science ®Google Scholar
• Couratier P, Desport JC, Torny F, et al. Modalités et contenu de l’annonce du diagnostic de sclérose latérale amyotrophique sporadique. Rev Neurol (Paris). 2006;162:4S108–4S12.
   PubMed Web of Science ®Google Scholar
• Borasio GD, Sloan R, Pongratz DE. Breaking the news in amyotrophic lateral sclerosis. J Neurol Sci. 1998;160:S127–S133.
   PubMed Web of Science ®Google Scholar
• Chiò A, Borasio GD. Breaking the news in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:195–201.
   PubMed Web of Science ®Google Scholar
• Chiò A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009;10:310–323.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13:1127–1138.
   PubMed Web of Science ®Google Scholar
• Jenkins TM, Hollinger H, McDermott CJ. The evidence for symptomatic treatments in amyotrophic lateral sclerosis. Curr Opin Neurol. 2014;27:524–531.
   PubMed Web of Science ®Google Scholar
• Hardiman O. Symptomatic treatment of respiratory and nutritional failure in amyotrophic lateral sclerosis. J Neurol. 2000;247:245–251.
   PubMed Web of Science ®Google Scholar
• Couratier P, Desport JC, Antonini MT, et al. Prise en charge nutritionnelle et respiratoire des patients atteints de sclérose latérale amyotrophique (SLA). Rev Neurol (Paris). 2004;160:243–250.
   PubMed Web of Science ®Google Scholar
• Pinto S, Carvalho M. Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients. Neurodegener Dis Manag. 2014;4:83–102.
   PubMedGoogle Scholar
• Gruis KL, Lechtzin N. Respiratory therapies for amyotrophic lateral sclerosis: a primer. Muscle Nerve. 2012;46:313–331.
   PubMed Web of Science ®Google Scholar
• Boentert M, Brenscheidt I, Glatz C, et al. Effects of non-invasive ventilation on objective sleep and nocturnal respiration in patients with amyotrophic lateral sclerosis. J Neurol. 2015;262:2073–2082.
   PubMed Web of Science ®Google Scholar
• McDermott CJ, Bradburn MJ, Maguire C, et al. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2015;14:883–892.
   PubMed Web of Science ®Google Scholar
• Barthlen GM, Lange DJ. Unexpectedly severe sleep and respiratory pathology in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2000;7:299–302.
   PubMed Web of Science ®Google Scholar
• Limousin N, Blasco H, Corcia P, et al. The high frequency of restless legs syndrome in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:303–306.
   PubMed Web of Science ®Google Scholar
• Ahmed RM, Newcombe RE, Piper AJ, et al. Sleep disorders and respiratory function in amyotrophic lateral sclerosis. Sleep Med Rev. 2015;26:33–42.
   PubMed Web of Science ®Google Scholar
• Abdelnour-Mallet M, Verschueren A, Guy N, et al. Safety of home parenteral nutrition in patients with amyotrophic lateral sclerosis: a French national survey. Amyotroph Lateral Scler. 2011;12:178–184.
   PubMed Web of Science ®Google Scholar
• Silani V, Kasarskis EJ, Yanagisawa N. Nutritional management in amyotrophic lateral sclerosis: a worldwide perspective. J Neurol. 1998;245:S13–S19; discussion S29.
   PubMed Web of Science ®Google Scholar
• Zhang M, Hubbard J, Rudnicki SA, et al. Survey of current enteral nutrition practices in treatment of amyotrophic lateral sclerosis. Espen J. 2013;8:e25–e28.
   PubMedGoogle Scholar
• Desport JC, Couratier P. Evaluation de l’état nutritionnel lors de la sclérose latérale amyotrophique. Rev Neurol (Paris). 2006;162:4S173–4S6.
   PubMed Web of Science ®Google Scholar
• Chio A, Galletti R, Finocchiaro C, et al. Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. J Neurol Neurosurg Psychiatry. 2004;75:645–647.
   PubMed Web of Science ®Google Scholar
• Gregory S, Siderowf A, Golaszewski AL, et al. Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survival. Neurology. 2002;58:485–487.
   PubMed Web of Science ®Google Scholar
• Sarfaty M, Nefussy B, Gross D, et al. Outcome of percutaneous endoscopic gastrostomy insertion in patients with amyotrophic lateral sclerosis in relation to respiratory dysfunction. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:528–532.
   PubMed Web of Science ®Google Scholar
• Sancho J, Servera E, Chiner E, et al. Noninvasive respiratory muscle aids during PEG placement in ALS patients with severe ventilatory impairment. J Neurol Sci. 2010;297:55–59.
   PubMed Web of Science ®Google Scholar
• ProGas Study Group. Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. Lancet Neurol. 2015;14:702–709.
   PubMed Web of Science ®Google Scholar
• Katzberg HD, Barros DF, Widrow B, et al. Analysis of continuous diaphragm electromyographic signal: results from a patient with amyotrophic lateral sclerosis. Muscle Nerve. 2011;43:801–806.
   PubMed Web of Science ®Google Scholar
• Tysnes O-B. Treatment of sialorrhea in amyotrophic lateral sclerosis. Acta Neurol Scand Suppl. 2008;188:77–81.
   PubMedGoogle Scholar
• Kasarskis EJ, Hodskins J, St Clair WH. Unilateral parotid electron beam radiotherapy as palliative treatment for sialorrhea in amyotrophic lateral sclerosis. J Neurol Sci. 2011;308:155–157.
   PubMed Web of Science ®Google Scholar
• Gibbons CJ, Thornton EW, Young CA. The patient experience of fatigue in motor neurone disease. Front Psychol. 2013;4:788.
   PubMed Web of Science ®Google Scholar
• Gibbons CJ, Mills RJ, Thornton EW, et al. Development of a patient reported outcome measure for fatigue in motor neurone disease: the Neurological Fatigue Index (NFI-MND). Health Qual Life Outcomes. 2011;9:101.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H. Amyotrophic lateral sclerosis. A guide to patients and families. New York (NY): Demos Medical Publishing; 2009.
   Google Scholar
• Beghi E, Logroscino G, Chio A, et al. Amyotrophic lateral sclerosis, physical exercise, trauma and sports: results of a population-based pilot case-control study. Amyotroph Lateral Scler. 2010;11:289–292.
   PubMed Web of Science ®Google Scholar
• Dalbello-Haas V, Florence JM, Krivickas LS. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2008;2:CD005229.
   PubMed Web of Science ®Google Scholar
• Pupillo E, Messina P, Giussani G, et al. Physical activity and amyotrophic lateral sclerosis: a European population-based case-control study. Ann Neurol. 2014;75:708–716.
   PubMed Web of Science ®Google Scholar
• Stephens HE, Lehman E, Raheja D, et al. Pain in amyotrophic lateral sclerosis: patient and physician perspectives and practices. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17:21–29.
   PubMed Web of Science ®Google Scholar
• Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012;4:CD004157.
   PubMed Web of Science ®Google Scholar
• Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012;2:CD004156.
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Albert SM, Del Bene ML, et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology. 2005;65:62–67.
   PubMed Web of Science ®Google Scholar
• Cui F, Zhu W, Zhou Z, et al. Frequency and risk factor analysis of cognitive and anxiety-depressive disorders in patients with amyotrophic lateral sclerosis/motor neuron disease. Neuropsychiatr Dis Treat. 2015;11:2847–2854.
   PubMed Web of Science ®Google Scholar
• Canosa A, Pagani M, Cistaro A, et al. 18F-FDG-PET correlates of cognitive impairment in ALS. Neurology. 2016;86:44–49.
   PubMed Web of Science ®Google Scholar
• Machts J, Loewe K, Kaufmann J, et al. Basal ganglia pathology in ALS is associated with neuropsychological deficits. Neurology. 2015;85:1301–1309.
   PubMed Web of Science ®Google Scholar
• Elamin M, Phukan J, Bede P, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology. 2011;76:1263–1269.
   PubMed Web of Science ®Google Scholar
• Connolly S, Galvin M, Hardiman O. End-of-life management in patients with amyotrophic lateral sclerosis. Lancet Neurol. 2015;14:435–442.
   PubMed Web of Science ®Google Scholar
• Boersma I, Miyasaki J, Kutner J, et al. Palliative care and neurology: time for a paradigm shift. Neurology. 2014;83:561–567.
   PubMed Web of Science ®Google Scholar
• Benditt JO, Smith TS, Tonelli MR. Empowering the individual with ALS at the end-of-life: disease-specific advance care planning. Muscle Nerve. 2001;24:1706–1709.
   PubMed Web of Science ®Google Scholar
• Shaw JM, Brown RF, Dunn SM. A qualitative study of stress and coping responses in doctors breaking bad news. Patient Educ Couns. 2013;91:243–248.
   PubMed Web of Science ®Google Scholar
• Shaw J, Brown R, Heinrich P, et al. Doctors’ experience of stress during simulated bad news consultations. Patient Educ Couns. 2013;93:203–208.
   PubMed Web of Science ®Google Scholar
• Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)–revised report of an EFNS task force. Eur J Neurol. 2012;19:360–375.
   PubMed Web of Science ®Google Scholar
• Bede P, Oliver D, Stodart J, et al. Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives. J Neurol Neurosurg Psychiatry. 2011;82:413–418.
   PubMed Web of Science ®Google Scholar
• Kiernan MC. Palliative care in amyotrophic lateral sclerosis. Lancet Neurol. 2015;14:347–348.
   PubMed Web of Science ®Google Scholar
• Pagnini F. Psychological wellbeing and quality of life in amyotrophic lateral sclerosis: a review. Int J Psychol. 2013;48:194–205.
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Goetz R, Factor-Litvak P, et al. Depression and wish to die in a multicenter cohort of ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:265–273.
   PubMed Web of Science ®Google Scholar
• Maessen M, Veldink JH, Onwuteaka-Philipsen BD, et al. Euthanasia and physician-assisted suicide in amyotrophic lateral sclerosis: a prospective study. J Neurol. 2014;261:1894–1901.
   PubMed Web of Science ®Google Scholar